drugset / Trial / NCT01797978

Methylene Blue in Severe Sepsis and Septic Shock

NCT01797978

Phase 3 Unknown 354 enrolled Seoul National University Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

This study is to see whether the intravenous administration of methylene blue improves the outcome in severe sepsis and septic shock.

Timeline

Start
2013-02
Primary completion
2016-01
Completion
2017-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylene Blue Diagnostic / imaging agent 0.5 mg/kg Intravenous